Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/22217
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShah, M D-
dc.contributor.authorDesai, N C-
dc.contributor.authorAwasthi, Keshav K-
dc.contributor.authorSaxena, Anil K-
dc.date.accessioned2013-10-18T05:05:55Z-
dc.date.available2013-10-18T05:05:55Z-
dc.date.issued2001-03-
dc.identifier.issn0975-0983(Online); 0376-4699(Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/22217-
dc.description201-208en_US
dc.description.abstractSeveral 2-[(4-arylmethylene-5-oxo-2-phenyl-1-imidazolinyl)amino]-N-(4-nitropheny l)acetamides 1,2-[(4-arylmethylene-5-oxo-2-phenyl-1-imidazolinyl)amino]-N-benzy lacetamides 2, 2-(4-chlorophenyl)-N-(4-arylmethylene-5-oxo-2- phenyl-1-imidazolinyl) acetamides 3 and N-(4-arylmethylene-5-oxo-2-phenyl-1-imidazolinyl)-N1-(2,6-dimethylphenyl)thioureas 4 have been synthesised and evaluated for their antibacterial act ivity against gram (+)ve S. aureus and gram (-)ve E. Coli bacteria. Most of the compounds have shown moderate to good activity against gram (+)ve and gram (-)ve bacteria. Correlation studies between the two models of anti bacterial screening have established the complementarity between the two models. The QSAR studies of these compounds have been carried out in terms of structural and physicochemical parameters where positive contribution by bulky lipophilic groups with increased electropositive character in the aryl part at 4-position of imidazolinones 1 has been observed.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJC-B Vol.40B(03) [March 2001]en_US
dc.titleSyntheses and QSAR studies of 5-imidazolinone derivatives as potential antibacterial agentsen_US
dc.typeArticleen_US
Appears in Collections:IJC-B Vol.40B(03) [March 2001]

Files in This Item:
File Description SizeFormat 
IJCB 40B(3) 201-208.pdf3.46 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.